Virtual Bioengineering Meet: NIH Plans for Backup Woes
Published Date: 12/22/2025
Notice
Summary
The National Institute of Biomedical Imaging and Bioengineering is holding a virtual meeting on January 28, 2026, to discuss important updates and review grant applications. Part of the meeting will be closed to protect private info and trade secrets. This affects researchers waiting on funding decisions and keeps the grant review process fair and secure.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NIH grant review meeting dates
If you applied for an NIH grant, the National Advisory Council for Biomedical Imaging and Bioengineering will review applications on January 28, 2026 (open 12:00 p.m. to 4:00 p.m.; closed 4:10 p.m. to 5:00 p.m.). A backup meeting is scheduled for March 19, 2026 (closed 12:00 p.m. to 3:00 p.m.) to finish any reviews not completed on January 28.
Closed sessions protect applicant confidentiality
Portions of the meetings are closed under 5 U.S.C. 552b(c)(4) and (c)(6) to review grant applications and protect confidential trade secrets, commercial property (such as patentable material), and personal information of applicants. The January 28 closed session is 4:10 p.m. to 5:00 p.m.; the March 19 session (if held) is 12:00 p.m. to 3:00 p.m.
Public access and comment instructions
The open portion of the January 28, 2026 meeting (12:00 p.m. to 4:00 p.m.) is available via NIH Videocast at http://videocast.nih.gov/ and on the NIBIB advisory council web page. Interested persons may file written comments with the committee by sending a statement (including name, address, telephone number, and affiliation when applicable) to the contact person, and those needing accommodations should notify the contact person in advance (Contact: Anna Taylor, Ph.D., (240) 402-5683).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-23597, National Institute on Aging; Notice of Meeting
The National Institute on Aging is holding a hybrid meeting on March 30-31, 2026, to review research labs and principal investigators (PIs). Some parts of the meeting will be open to the public, while others will be closed to protect privacy. This meeting affects researchers seeking grants and helps decide who gets funding and support.
Next: 2025-23599, Proposed Data Collection Submitted for Public Comment and Recommendations
The Agency for Toxic Substances and Disease Registry wants your thoughts on their plan to keep collecting info about people with ALS, a serious disease. This helps them understand how many people have ALS and what might cause it. If you want to share your opinion, you have until February 20, 2026, to comment—no money changes, just a chance to help shape the data collection.